17^th European Biosimilars Congress

USFDA Approved Biosimilars

The USFDA has been actively approving biosimilars to increase patient access to more affordable treatment options. Some notable USFDA-approved biosimilars include those for reference biologics such as adalimumab, infliximab, and trastuzumab. These biosimilars have undergone rigorous evaluations to demonstrate similarity in terms of safety, efficacy, and quality to their respective reference products. The USFDA's approval of these biosimilars provides healthcare providers and patients with alternatives that offer similar clinical benefits while potentially reducing healthcare costs. The expanding portfolio of USFDA-approved biosimilars signifies the growing acceptance and adoption of these products in the United States, contributing to increased competition and improved accessibility to critical biologic therapies.